Healthcare professionals (HCPs), particularly endocrinologists, who specialize in the management and treatment of patients with type 2 diabetes.

Module 1:
• GLP-1 RA position in T2D treatment continuum
• Glycemic treatment effects

Module 2:
• Extra-glycemic treatment effects, including GLP-1 RA impacts on CV, liver and other organ systems
• Adverse treatment effects and contraindications

Module 3:
• Dosing considerations for diverse patients – Daily vs Weekly, Renal and Hepatic disease, diabetes alone or obesity?
• Shared decision making based on DEI considerations in the planning of T2D treatment plans

Module 4:
• GLP-1 RA mechanism of action
• Mode of administration – discuss oral vs SQ.

Upon completing this activity, learners should be able to:

• Define, discuss, and differentiate currently available GLP-1 RAs for T2D treatment
• Plan, implement, and monitor long-term treatment plans, inclusive of GLP-1 RA therapies for appropriate patients, for diverse presentations of T2D
• Critically evaluate short- and long-term GLP-1 RA treatment outcomes for diverse patients with T2D

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the the Endocrine Society. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 4 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Rodolfo Galindo, MD 
Associate Professor of Medicine
Director, Comprehensive Diabetes Center, UM Health System
Director, Diabetes Services, Jackson Memorial Hospital 

Cyrus V. Desouza, MBBS, FACP, FACE
Chief, Division of Diabetes, Endocrinology & Metabolism
Professor, Division of Diabetes, Endocrinology & Metabolism
Director, Diabetes & Obesity program, Omaha VA Medical Center

Marconi Abreu, MD
Associate Professor
Department of Internal Medicine, UT Southwestern Medical 

Tina Vilsbøll, MD, DMSc
Clinical Professor
Head of Clinic, Steno Diabetes Center, Copenhagen, Denmark 

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:


Rodolfo Galindo, MD - Novo Nordisk – Research Grant, Consulting and Advisory; Eli Lilly – Research Grant, Consulting and Advisory; Dexcom – Research Grant; Sanofi – Consulting and Advisory; Pfizer - Consulting and Advisory; Boehringer - Consulting and Advisory; Bayer - Consulting and Advisory; Weight Watchers - Consulting and Advisory; National Institute of Diabetes and Digestive and Kidney Diseases – Grant Award; National Institute of Health – Grant Award.

Cyrus V. Desouza, MBBS, FACP, FACE - Journal of Diabetes and Complications, Associate Editor; Novo Nordisk, Global Expert Panel; AstraZeneca, Advisory Panel; Bayer, Asahi, Magdrigal, Merck, Advisory Board

Tina Vilsbøll, MD, DMSc - Served on scientific advisory panels, speaker's bureaus, and as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi and Sun Pharmaceuticals. 

The following faculty reported no relevant financial relationships:
Marconi Abreu, MD

The following committee member who planned and reviewed content for this activity reported no relevant financial relationships: 
Milay Luis Lam, MD

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Novo Nordisk